275 related articles for article (PubMed ID: 18804521)
1. Synthesis and evaluation of dextran-budesonide conjugates as colon specific prodrugs for treatment of ulcerative colitis.
Varshosaz J; Emami J; Tavakoli N; Fassihi A; Minaiyan M; Ahmadi F; Dorkoosh F
Int J Pharm; 2009 Jan; 365(1-2):69-76. PubMed ID: 18804521
[TBL] [Abstract][Full Text] [Related]
2. Preparation of budesonide-dextran conjugates using glutarate spacer as a colon-targeted drug delivery system: in vitro/in vivo evaluation in induced ulcerative colitis.
Varshosaz J; Emami J; Ahmadi F; Tavakoli N; Minaiyan M; Fassihi A; Mahzouni P; Dorkoosh F
J Drug Target; 2011 Feb; 19(2):140-53. PubMed ID: 20429772
[TBL] [Abstract][Full Text] [Related]
3. Preparation and in vitro/in vivo evaluation of dextran matrix tablets of budesonide in experimental ulcerative colitis in rats.
Ahmadi F; Varshosaz J; Emami J; Tavakoli N; Minaiyan M; Mahzouni P; Dorkoosh F
Drug Deliv; 2011 Feb; 18(2):122-30. PubMed ID: 20954795
[TBL] [Abstract][Full Text] [Related]
4. Microencapsulation of budesonide with dextran by spray drying technique for colon-targeted delivery: an in vitro/in vivo evaluation in induced colitis in rat.
Varshosaz J; Ahmadi F; Emami J; Tavakoli N; Minaiyan M; Mahzouni P; Dorkoosh F
J Microencapsul; 2011; 28(1):62-73. PubMed ID: 21171817
[TBL] [Abstract][Full Text] [Related]
5. Central composite design for the formulation and optimization of a multi-unit potential colonic drug delivery system of budesonide for ulcerative colitis.
Patel NV; Patel JK; Shah SH; Patel JN
Pharmazie; 2011 Feb; 66(2):124-9. PubMed ID: 21434575
[TBL] [Abstract][Full Text] [Related]
6. Glucocorticoid-dextran conjugates as potential prodrugs for colon-specific delivery: hydrolysis in rat gastrointestinal tract contents.
McLeod AD; Friend DR; Tozer TN
J Pharm Sci; 1994 Sep; 83(9):1284-8. PubMed ID: 7530303
[TBL] [Abstract][Full Text] [Related]
7. Budesonide-beta-D-glucuronide: a potential prodrug for treatment of ulcerative colitis.
Nolen H; Fedorak RN; Friend DR
J Pharm Sci; 1995 Jun; 84(6):677-81. PubMed ID: 7562403
[TBL] [Abstract][Full Text] [Related]
8. Colon-targeted delivery of budesonide using dual pH- and time-dependent polymeric nanoparticles for colitis therapy.
Naeem M; Choi M; Cao J; Lee Y; Ikram M; Yoon S; Lee J; Moon HR; Kim MS; Jung Y; Yoo JW
Drug Des Devel Ther; 2015; 9():3789-99. PubMed ID: 26229440
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of budesonide-succinate-dextran conjugate as a novel prodrug of budesonide against acetic acid-induced colitis in rats.
Varshosaz J; Emami J; Fassihi A; Tavakoli N; Minaiyan M; Ahmadi F; Mahzouni P; Dorkoosh F
Int J Colorectal Dis; 2010 Oct; 25(10):1159-65. PubMed ID: 20669022
[TBL] [Abstract][Full Text] [Related]
10. Characterization of a dextran-budesonide prodrug for inhalation therapy.
Waters RC; Hochhaus G
Eur J Pharm Sci; 2019 Mar; 129():58-67. PubMed ID: 30521945
[TBL] [Abstract][Full Text] [Related]
11. [Characteristics of drug-release in vitro of different dextran-dexamethasone conjugates].
Zhou SY; Mei QB; Liu L; Zhang BL; Li C; Zhou J
Yao Xue Xue Bao; 2003 May; 38(5):388-91. PubMed ID: 12958847
[TBL] [Abstract][Full Text] [Related]
12. Delivery of glucocorticoid conjugate in rat gastrointestinal tract and its treatment for ulcerative colitis.
Zhou SY; Mei QB; Liu L; Guo X; Qiu BS; Zhao DH; Cho CH
Acta Pharmacol Sin; 2001 Aug; 22(8):761-4. PubMed ID: 11749853
[TBL] [Abstract][Full Text] [Related]
13. Colon specific delivery of budesonide based on triple coated pellets: in vitro/in vivo evaluation.
Varshosaz J; Emami J; Tavakoli N; Minaiyan M; Rahmani N; Dorkoosh F; Mahzouni P
Acta Pharm; 2012 Nov; 62(3):341-56. PubMed ID: 23470347
[TBL] [Abstract][Full Text] [Related]
14. Colon delivery of budesonide using solid dispersion in dextran for the treatment and secondary prevention of ulcerative colitis in rat.
Varshosaz J; Ahmadi F; Emami J; Tavakoli N; Minaiyan M; Mahzouni P; Dorkoosh F
Int J Prev Med; 2010; 1(2):115-23. PubMed ID: 21566772
[TBL] [Abstract][Full Text] [Related]
15. Glucocorticoid-dextran conjugates as potential prodrugs for colon-specific delivery: steady-state pharmacokinetics in the rat.
McLeod AD; Tolentino L; Tozer TN
Biopharm Drug Dispos; 1994 Mar; 15(2):151-61. PubMed ID: 7516722
[TBL] [Abstract][Full Text] [Related]
16. Design and development of liposomes for colon targeted drug delivery.
Gupta AS; Kshirsagar SJ; Bhalekar MR; Saldanha T
J Drug Target; 2013 Feb; 21(2):146-60. PubMed ID: 23373543
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and in vitro characterization of novel dextran-methylprednisolone conjugates with peptide linkers: effects of linker length on hydrolytic and enzymatic release of methylprednisolone and its peptidyl intermediates.
Penugonda S; Kumar A; Agarwal HK; Parang K; Mehvar R
J Pharm Sci; 2008 Jul; 97(7):2649-64. PubMed ID: 17853426
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and properties of dextran-nalidixic acid ester as a colon-specific prodrug of nalidixic acid.
Lee JS; Jung YJ; Doh MJ; Kim YM
Drug Dev Ind Pharm; 2001 Apr; 27(4):331-6. PubMed ID: 11411900
[TBL] [Abstract][Full Text] [Related]
19. Ketorolac-dextran conjugates: synthesis, in vitro and in vivo evaluation.
Vyas S; Trivedi P; Chaturvedi SC
Acta Pharm; 2007 Dec; 57(4):441-50. PubMed ID: 18165188
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of dextran-flufenamic acid ester as a polymeric colon-specific prodrug of flufenamic acid, an anti-inflammatory drug, for chronotherapy.
Lee Y; Kim IH; Kim J; Yoon JH; Shin YH; Jung Y; Kim YM
J Drug Target; 2011 Jun; 19(5):336-43. PubMed ID: 20615092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
